Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Published byNicole Piché Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,"— Presentation transcript:

1 Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas, MD, Nicola Wagner, MD, Jörg Fischer, MD, Karsten Weller, MD, Martin Metz, MD, Martin K. Church, PhD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 139, Issue 4, Pages (April 2017) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Subject disposition showing the number of screened, randomized, and completed patients. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Changes in disease activity. A, Responder rates at day 7. Red, complete responders; pink, partial responders to canakinumab; light blue, partial responders to placebo; gray, nonresponders. Absolute patient numbers are indicated in the bars. B, PGA. The light gray areas indicate minimal disease activity. C, Representative patient images. D, The overall Schnitzler activity score for 7 days before and 7 days after treatment with canakinumab 150 mg or placebo. Asterisks indicate a significant (*P ≤ .05; **P ≤ .01) difference from placebo. Changes in overall Schnitzler activity scores correlated with changes in total PGA scores (r = 0.595; P = .012). n.s., Nonsignificant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Changes in inflammation markers and IL-1Ra levels. A, CRP levels. B, SAA levels. C, S100A12 levels. D, IL-1Ra levels. The light gray areas indicate normal values. Changes in CRP, SAA, and IL-1Ra levels correlated with changes in total PGA scores (CRP: r = 0.748, P < .0001; SAA: r = 0.585, P = .011; IL-1Ra: r = 0.600, P = .018). Changes in S100A12 values followed changes in PGA urticarial rash scores (r = 0.556, P = .025) but not PGA total scores. n.s., Nonsignificant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Changes in quality-of-life scores. A, DLQI scores. B, SF-36 physical component summary scores. C, SF-36 mental component summary scores. The light gray areas indicate reference values (physical component, 44.81; mental component, 53.18) of an age-matched (61-70 years) German healthy population. Changes in DLQI sum scores and SF-36 physical component summary scores correlated with changes in PGA total scores (DLQI: r = 0.487, P = .034; SF-36 physical component summary: r = 0.780, P < .0001). n.s., Nonsignificant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Individual duration of clinical improvement following canakinumab administration during open-label treatment. Red arrows indicate individual time points of relapsing symptoms and subsequent canakinumab treatment. Asterisks indicate ongoing clinical improvement beyond day 120. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M

Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Similar presentations

Ads by Google